• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis.冠心病监护病房中的高脂蛋白(a)血症与家族性高胆固醇血症:腹背受敌。
Clin Cardiol. 2018 Mar;41(3):378-384. doi: 10.1002/clc.22880. Epub 2018 Feb 26.
2
Familial Hypercholesterolemia, Familial Combined Hyperlipidemia, and Elevated Lipoprotein(a) in Patients With Premature Coronary Artery Disease.早发性冠状动脉疾病患者中的家族性高胆固醇血症、家族性混合型高脂血症和脂蛋白(a)升高
Can J Cardiol. 2021 Nov;37(11):1733-1742. doi: 10.1016/j.cjca.2021.08.012. Epub 2021 Aug 26.
3
Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia.脂蛋白(a)升高、高血压和肾功能不全作为基因确诊的杂合子家族性高胆固醇血症患者冠状动脉疾病的预测因素。
Int J Cardiol. 2015 Dec 15;201:633-8. doi: 10.1016/j.ijcard.2015.08.146. Epub 2015 Aug 21.
4
Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease.脂蛋白(a)水平在家族性高胆固醇血症和冠状动脉疾病中的意义。
Atherosclerosis. 2017 May;260:67-74. doi: 10.1016/j.atherosclerosis.2017.03.021. Epub 2017 Mar 18.
5
Lipoprotein(a) screening in young and middle-aged patients presenting with acute coronary syndrome.对出现急性冠脉综合征的中青年患者进行脂蛋白(a)筛查。
Cardiol J. 2019;26(5):511-518. doi: 10.5603/CJ.a2018.0106. Epub 2018 Sep 20.
6
Familial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: Frequencies, associations and predictions.家族性混合性高脂血症和高脂蛋白(a)作为家族性高胆固醇血症的表型模拟物:发生率、关联及预测
J Clin Lipidol. 2016 Nov-Dec;10(6):1329-1337.e3. doi: 10.1016/j.jacl.2016.08.011. Epub 2016 Aug 26.
7
Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit.入住冠心病监护病房的早发性冠状动脉疾病患者中家族性高胆固醇血症的发生率。
J Clin Lipidol. 2015 Sep-Oct;9(5):703-8. doi: 10.1016/j.jacl.2015.07.005. Epub 2015 Jul 18.
8
Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia.在家族性高胆固醇血症的级联检测中测量脂蛋白(a)的价值。
J Am Coll Cardiol. 2019 Mar 12;73(9):1029-1039. doi: 10.1016/j.jacc.2018.12.037.
9
Elevated lipoprotein(a) and low-density lipoprotein cholesterol as predictors of the severity and complexity of angiographic lesions in patients with premature coronary artery disease.脂蛋白(a)和低密度脂蛋白胆固醇升高可预测早发冠心病患者血管造影病变的严重程度和复杂性。
J Clin Lipidol. 2018 Jul-Aug;12(4):1019-1026. doi: 10.1016/j.jacl.2018.03.090. Epub 2018 Apr 3.
10
The Prevalence of Elevated Lipoprotein(a) in Patients Presenting With Coronary Artery Disease.脂蛋白(a)升高在冠心病患者中的流行情况。
Heart Lung Circ. 2020 Nov;29(11):1682-1687. doi: 10.1016/j.hlc.2020.03.005. Epub 2020 Apr 1.

引用本文的文献

1
Association Between Lipoprotein(a) and Arterial Stiffness in Young Adults with Familial Hypercholesterolemia.家族性高胆固醇血症青年成人中脂蛋白(a)与动脉僵硬度之间的关联
J Clin Med. 2025 Feb 27;14(5):1611. doi: 10.3390/jcm14051611.
2
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy.依洛尤单抗治疗纯合子家族性高胆固醇血症:长期安全性和疗效。
Eur Heart J. 2024 Jul 12;45(27):2422-2434. doi: 10.1093/eurheartj/ehae325.
3
Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPN.纯合子家族性高胆固醇血症患儿脂蛋白分离术的临床实践建议:ERKNet和ESPN的专家共识声明
medRxiv. 2023 Nov 15:2023.11.14.23298547. doi: 10.1101/2023.11.14.23298547.
4
Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.依洛尤单抗在治疗儿童纯合子家族性高胆固醇血症中的应用。
Circulation. 2024 Jan 30;149(5):343-353. doi: 10.1161/CIRCULATIONAHA.123.065529. Epub 2023 Oct 20.
5
Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia.载脂蛋白(a)基因型影响家族性高胆固醇血症的临床诊断。
J Am Heart Assoc. 2023 May 16;12(10):e029223. doi: 10.1161/JAHA.122.029223. Epub 2023 May 15.
6
Lipoprotein(a) levels in children with suspected familial hypercholesterolaemia: a cross-sectional study.疑似家族性高胆固醇血症患儿的脂蛋白(a)水平:一项横断面研究。
Eur Heart J. 2023 Apr 21;44(16):1421-1428. doi: 10.1093/eurheartj/ehac660.
7
Prevention of Atherosclerotic Cardiovascular Disease in Children with Familial Hypercholesterolemia.预防家族性高胆固醇血症儿童的动脉粥样硬化性心血管疾病。
Curr Atheroscler Rep. 2021 Aug 27;23(10):64. doi: 10.1007/s11883-021-00959-8.
8
Lipoprotein(a) as a unique primary risk factor for early atherosclerotic peripheral arterial disease.脂蛋白(a)作为早发性动脉粥样硬化外周动脉疾病的独特首要危险因素。
BMJ Case Rep. 2021 Jun 30;14(6):e243231. doi: 10.1136/bcr-2021-243231.
9
Familial Hypercholesterolemia in Asia Pacific: A Review of Epidemiology, Diagnosis, and Management in the Region.亚太地区家族性高胆固醇血症:该地区流行病学、诊断和管理的综述。
J Atheroscler Thromb. 2021 May 1;28(5):417-434. doi: 10.5551/jat.56762. Epub 2021 Mar 19.
10
Risk of cardiovascular disease with lipoprotein(a) in familial hypercholesterolemia: a review.家族性高胆固醇血症中脂蛋白(a)与心血管疾病风险:综述
Arch Med Sci Atheroscler Dis. 2020 Jul 11;5:e148-e152. doi: 10.5114/amsad.2020.97105. eCollection 2020.

本文引用的文献

1
The renaissance of lipoprotein(a): Brave new world for preventive cardiology?脂蛋白(a)的复兴:预防心脏病学的崭新时代?
Prog Lipid Res. 2017 Oct;68:57-82. doi: 10.1016/j.plipres.2017.09.001. Epub 2017 Sep 6.
2
Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention.经皮冠状动脉介入治疗中传统危险因素控制患者的脂蛋白(a)筛查。
J Clin Lipidol. 2017 Sep-Oct;11(5):1177-1180. doi: 10.1016/j.jacl.2017.07.005. Epub 2017 Jul 22.
3
Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia.用于家族性高胆固醇血症早期检测的级联筛查项目的成本效益
J Clin Lipidol. 2017 Jan-Feb;11(1):260-271. doi: 10.1016/j.jacl.2017.01.002. Epub 2017 Jan 10.
4
Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study).预测家族性高胆固醇血症中的心血管事件:SAFEHEART 登记研究(西班牙家族性高胆固醇血症队列研究)。
Circulation. 2017 May 30;135(22):2133-2144. doi: 10.1161/CIRCULATIONAHA.116.024541. Epub 2017 Mar 8.
5
Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study.理想的心血管健康状况会影响与高脂蛋白(a)水平及基因型相关的心血管疾病风险:欧洲癌症与营养前瞻性调查诺福克前瞻性人群研究。
Atherosclerosis. 2017 Jan;256:47-52. doi: 10.1016/j.atherosclerosis.2016.11.010. Epub 2016 Nov 11.
6
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease.遗传风险、对健康生活方式的坚持与冠心病
N Engl J Med. 2016 Dec 15;375(24):2349-2358. doi: 10.1056/NEJMoa1605086. Epub 2016 Nov 13.
7
Identification of familial hypercholesterolemia in patients with myocardial infarction: A Chinese cohort study.心肌梗死患者中家族性高胆固醇血症的识别:一项中国队列研究。
J Clin Lipidol. 2016 Nov-Dec;10(6):1344-1352. doi: 10.1016/j.jacl.2016.08.013. Epub 2016 Sep 2.
8
Identification and characterization of severe familial hypercholesterolemia in patients presenting for cardiac catheterization.对因心脏导管插入术就诊患者中严重家族性高胆固醇血症的识别与特征分析。
J Clin Lipidol. 2016 Nov-Dec;10(6):1338-1343. doi: 10.1016/j.jacl.2016.08.010. Epub 2016 Aug 27.
9
The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction.心肌梗死患者中可能存在的家族性高胆固醇血症的患病率及其预后重要性。
Am Heart J. 2016 Nov;181:35-42. doi: 10.1016/j.ahj.2016.08.001. Epub 2016 Aug 10.
10
Familial hypercholesterolemia among unselected contemporary patients presenting with first myocardial infarction: Prevalence, risk factor burden, and impact on age at presentation.未筛选的首发心肌梗死患者中的家族性高胆固醇血症:患病率、危险因素负担以及对发病年龄的影响。
J Clin Lipidol. 2016 Sep-Oct;10(5):1145-1152.e1. doi: 10.1016/j.jacl.2016.06.002. Epub 2016 Jun 14.

冠心病监护病房中的高脂蛋白(a)血症与家族性高胆固醇血症:腹背受敌。

Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis.

作者信息

Ellis Katrina L, Pang Jing, Chieng David, Bell Damon A, Burnett John R, Schultz Carl J, Hillis Graham S, Watts Gerald F

机构信息

School of Medicine, University of Western Australia, Perth, Australia.

School of Biomedical Sciences, University of Western Australia, Perth, Australia.

出版信息

Clin Cardiol. 2018 Mar;41(3):378-384. doi: 10.1002/clc.22880. Epub 2018 Feb 26.

DOI:10.1002/clc.22880
PMID:29480541
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6489753/
Abstract

BACKGROUND

Elevated lipoprotein(a) (Lp[a]) and familial hypercholesterolemia (FH) are inherited lipid disorders. Their frequencies, coexistence, and associations with premature coronary artery disease (CAD) in patients admitted to the coronary care unit (CCU) remain to be defined.

HYPOTHESIS

Elevated Lp(a) and FH are commonly encountered among CCU patients and independently associated with increased premature CAD risk.

METHODS

Plasma Lp(a) concentrations were measured in consecutive patients admitted to the CCU with an acute coronary syndrome (ACS) or prior history of CAD for 6.5 months. Elevated Lp(a) was defined as concentrations ≥0.5 g/L. Patients with LDL-C ≥ 5 mmol/L exhibited phenotypic FH. Premature CAD was diagnosed in those age < 60 years, and the relationship between this and elevated Lp(a) and FH was determined by logistic regression.

RESULTS

316 patients were screened; 163 (51.6%) had premature CAD. Overall, elevated Lp(a) and FH were identified in 27.0% and 11.6% of patients, respectively. Both disorders were detected in 4.4% of individuals. Elevated Lp(a) (32.0% vs 22.2%; P = 0.019) and FH phenotype (15.5% vs 8.0%; P = 0.052) were more common with premature vs nonpremature CAD. Elevated Lp(a) alone conferred a 1.9-fold, FH alone a 3.2-fold, and the combination a 5.3-fold increased risk of premature CAD (P = 0.005).

CONCLUSIONS

Elevated Lp(a) and phenotypic FH were commonly encountered and more frequent with premature CAD. The combination of both disorders is especially associated with increased CAD risk. Patients admitted to the CCU with ACS or previously documented CAD should be routinely screened for elevated Lp(a) and FH.

摘要

背景

脂蛋白(a)[Lp(a)]升高和家族性高胆固醇血症(FH)是遗传性脂质紊乱疾病。在冠心病监护病房(CCU)收治的患者中,它们的发生率、共存情况以及与早发冠状动脉疾病(CAD)的关联仍有待明确。

假设

CCU患者中Lp(a)升高和FH较为常见,且与早发CAD风险增加独立相关。

方法

对连续6.5个月入住CCU的急性冠状动脉综合征(ACS)患者或有CAD病史的患者测量血浆Lp(a)浓度。Lp(a)升高定义为浓度≥0.5g/L。低密度脂蛋白胆固醇(LDL-C)≥5mmol/L的患者表现为FH表型。早发CAD定义为年龄<60岁,通过逻辑回归确定其与Lp(a)升高和FH的关系。

结果

共筛查316例患者;163例(51.6%)有早发CAD。总体而言,分别在27.0%和11.6%的患者中发现Lp(a)升高和FH。4.4%的个体同时存在这两种疾病。与非早发CAD相比,早发CAD患者中Lp(a)升高(32.0%对22.2%;P=0.019)和FH表型(15.5%对8.0%;P=0.052)更为常见。单独Lp(a)升高使早发CAD风险增加1.9倍,单独FH使风险增加3.2倍,两者并存使风险增加5.3倍(P=0.005)。

结论

Lp(a)升高和FH表型在CCU患者中较为常见,在早发CAD患者中更频繁。两种疾病并存尤其与CAD风险增加相关。因ACS入住CCU或既往有CAD记录的患者应常规筛查Lp(a)升高和FH。